To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - AbbVie Inc. raised its full-year profit forecast due to strong demand for its psoriasis treatment Skyrizi, leading to third-quarter sales that exceeded expectations, although shares fell over 4% in intra-day trading [1] Financial Performance - For the quarter ending in September, AbbVie reported a net revenue increase of 9.1% year-over-year, reaching $15.78 billion, driven by strong sales of Skyrizi and Rinvoq [2] - Adjusted earnings per share for the quarter were $1.86, a decrease from $4.86 a year earlier, but above Bloomberg's consensus estimate of $1.77 [2] Product Performance - The growth in immunology products helped mitigate the decline in Humira, which has faced significant competition from lower-cost biosimilars since 2023 [3] - Rinvoq generated $5.97 billion in revenue in 2024, representing approximately half of AbbVie's total sales, with expectations that Rinvoq and Skyrizi will together contribute about $31 billion in revenue by 2027 [3]

Industry Overview - The global population is aging rapidly, with the number of individuals aged 60 and above surpassing those under five for the first time in 2020, leading to significant implications for healthcare systems and investors [2] - By 2050, nearly 22% of the global population will be over 60, with a significant concentration in low- and middle-income countries [2] - The geriatric care services industry is currently valued at approximately $1.21 trillion and is projected to grow to around $2.12 trillion by 2034, reflecting a compound annual growth rate (CAGR) of 6.4% [3] Market Dynamics - Evolving healthcare utilization patterns due to aging are creating growth opportunities in senior living communities, skilled nursing facilities, assisted living, and post-acute care providers [4] - The Centers for Medicare & Medicaid Services (CMS) has advanced the Program of All-Inclusive Care for the Elderly (PACE), aimed at providing comprehensive care for seniors [4] Key Players - Major healthcare companies like Boston Scientific, AbbVie, Amgen, and Edwards Lifesciences are actively expanding their presence in the senior and aging demographics [5] - The Ensign Group is expanding its skilled nursing and rehabilitative services, supported by a decentralized management strategy [7] - Healthcare real estate investment trusts (REITs) such as Omega Healthcare Investors and CareTrust REIT are focusing on skilled nursing and senior housing properties [7] Investment Perspective - The senior-care services sector is resilient during economic downturns, providing stable cash flows and making it attractive for long-term investors seeking defensive growth [8] Company Highlights - **Boston Scientific**: Focuses on medical devices for the elderly, including the WATCHMAN device for stroke risk reduction and the SYNERGY bioabsorbable stent system [9][10] - **AbbVie**: Expanding its focus on the aging demographic through strategic partnerships, including the acquisition of Aliada Therapeutics for Alzheimer's treatment [11][12][14] - **Amgen**: Targeting the aging population with innovations in biopharma, including obesity treatments and bone health therapies [15][16] - **Edwards Lifesciences**: Advancing care for aortic stenosis in elderly patients, with significant sales growth in structural-heart solutions [17][18][19]

Core Insights - AbbVie reported revenue of $15.78 billion for the quarter ended September 2025, reflecting a 9.1% increase year-over-year and surpassing the Zacks Consensus Estimate of $15.59 billion by 1.2% [1] - The company's EPS was $1.86, down from $3.00 in the same quarter last year, but exceeded the consensus estimate of $1.77 by 5.08% [1] Revenue Performance by Segment - Oncology (Elahere) generated $170 million, below the average estimate of $199.05 million, but showed a year-over-year increase of 22.3% [4] - Creon (US) reported $368 million, exceeding the estimate of $350.08 million, with an 8.9% year-over-year growth [4] - Rinvoq (International) achieved $625 million, surpassing the estimate of $606.08 million, marking a significant 40.8% increase year-over-year [4] - Humira (US) revenue was $619 million, significantly below the estimate of $764.72 million, reflecting a drastic year-over-year decline of 64.9% [4] - Neuroscience total revenue reached $2.84 billion, exceeding the estimate of $2.74 billion, with a year-over-year increase of 20.2% [4] - Vraylar total revenue was $934 million, slightly below the estimate of $946.65 million, showing a year-over-year growth of 6.7% [4] - Immunology total revenue was $7.89 billion, in line with the estimate of $7.88 billion, representing an 11.9% year-over-year increase [4] - Rinvoq total revenue was $2.18 billion, slightly above the estimate of $2.16 billion, with a year-over-year growth of 35.3% [4] - Botox Therapeutic total revenue was $985 million, exceeding the estimate of $922.4 million, with a year-over-year increase of 16.2% [4] - Juvederm Collection total revenue was $253 million, slightly below the estimate of $257.9 million, reflecting a year-over-year decline of 1.9% [4] - Botox Cosmetic total revenue was $637 million, below the estimate of $686.58 million, with a year-over-year decrease of 5.1% [4] - Imbruvica revenue was $706 million, slightly below the estimate of $708.25 million, showing a year-over-year decline of 14.7% [4] Stock Performance - AbbVie shares have returned -3.5% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change, indicating underperformance relative to the broader market [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the market in the near term [3]

Core Insights - AbbVie is facing pressure from the Trump administration for steeper cuts in Medicare drug price negotiations, with discounts potentially reaching up to 79% for certain drugs in 2024 [1] - The company reported a decline in quarterly sales of its aesthetic products, including Botox, which fell by 3.7% year-over-year, leading to a more than 4% drop in AbbVie shares [2] - AbbVie raised its 2025 profit forecast due to strong sales of newer immunology drugs, Skyrizi and Rinvoq, despite challenges in its aesthetics business [4][5] Group 1: Drug Price Negotiations - The Trump administration is advocating for deeper discounts in Medicare drug price negotiations, which are set to take effect in 2027 [2] - Last year, the Biden administration aimed to save $6 billion in 2026 through negotiations on top-selling prescription drugs, with AbbVie's Imbruvica facing a 38% cut [4] Group 2: Financial Performance - AbbVie expects adjusted annual profit per share for 2025 to be between $10.61 and $10.65, an increase from the previous expectation of $10.38 to $10.58 [5] - The company reported quarterly sales of $15.78 billion, surpassing analysts' average estimate of $15.59 billion, and anticipates fourth-quarter net sales of $16.3 billion for 2025 [7] Group 3: Market Challenges - The aesthetics business is experiencing headwinds, with concerns about the economy and inflation affecting customer spending [6][7] - Analysts have expressed concerns that continued weaker performance in the aesthetics segment could impact investor confidence [6]

Core Insights - AbbVie Inc. reported third-quarter 2025 sales of $15.78 billion, exceeding the consensus estimate of $15.59 billion, with a reported sales increase of 9.1% and an operational increase of 8.4% [1] - Adjusted earnings per share were $1.86, down 38% year-over-year, but above the consensus of $1.79 [1] - The company raised its quarterly dividend from $1.64 to $1.73 per share, reflecting confidence in its financial performance [1][2] Sales Performance - The immunology portfolio generated $7.89 billion in global net revenues, up 11.9% (+11.2% operationally), driven by Skyrizi sales of $4.71 billion (+46.8%) and Rinvoq sales of $2.18 billion (+35.3%); however, Humira sales fell to $993 million (-55.4%) [2] - The oncology portfolio saw sales of $1.68 billion, a slight decrease of 0.03% (-1.3%), with Imbruvica revenues at $706 million (-14.8%) and Venclexta revenues at $726 million (+7.1%) [3] - Neuroscience portfolio sales increased by 20.2% to $2.84 billion, with Vraylar revenues at $934 million (+6.7%) and Botox Therapeutics at $985 million (+16.1%) [3] Guidance and Future Outlook - AbbVie raised its fiscal 2025 adjusted earnings guidance to a range of $10.61-$10.65 per share, compared to the previous range of $10.38-$10.58, against a consensus of $10.53 [4] - The updated guidance accounts for a $2.05 per share negative impact from acquired IPR&D and milestone expenses incurred year-to-date [4] Analyst Commentary - Analysts from William Blair noted that AbbVie's immunology and inflammation franchises are exceeding expectations, contributing positively to total revenue growth [5] - There are anticipated growth drivers in the Parkinson's disease franchise and potential from the late-stage ADC portfolio [5] - AbbVie shares are currently trading at 15.8 times the 2026 consensus EPS, which does not fully reflect the company's growth profile, leading to an Outperform rating from analysts [6]

Market Overview - U.S. markets opened with positive momentum, with the Nasdaq up by 1%, S&P 500 increasing by 0.60%, and Dow Jones rising by 0.15% [2] - The Russell 2000 index also showed slight gains of 0.05% [2] Premarket Movers - Brighthouse Financial saw a significant increase of 23.4% amid takeover discussions [3] - Other notable gainers included Amazon (+12%), Twilio (+10%), Western Digital (+9.7%), Cloudflare (+8.7%), and Rocket Companies (+7.8%) following their earnings reports [3] Earnings Reports - Strong earnings from Amazon (+12.5% in premarket) and Apple (+2.2%) contributed positively to market sentiment, offsetting weaker performances from Microsoft and Meta [6] - Exxon Mobil, Abbvie, and Chevron also released their earnings, contributing to the overall market activity [7] Market Sentiment - The market is reacting positively to a combination of strong earnings reports and optimistic commentary from the U.S. central bank, despite the ongoing government shutdown which has halted the release of economic data [5][8]

Core Viewpoint - AbbVie reported better-than-expected adjusted earnings and revenue for the third quarter, but the stock declined due to mixed results across its drug portfolios [2][3]. Financial Performance - Adjusted earnings were $1.86 per share, exceeding the $1.77 consensus among analysts [3][6]. - Net revenue grew by 9.1% to $15.78 billion, slightly above the expected $15.59 billion [3][6]. Portfolio Performance - Revenue from the immunology portfolio increased by 12%, while the neuroscience portfolio saw a 20% increase [4][6]. - Revenue from the oncology portfolio declined by 0.3% to $1.682 billion [5][6]. - The aesthetics portfolio, which includes Botox Cosmetic, fell by 3.7% to $1.193 billion [5][7]. Product Highlights - Sales of the blockbuster biologic drugs Skyrizi and Rinvoq increased by double digits compared to the same period last year [4]. - Revenue from the anti-inflammatory drug Humira dropped by 55% to $993 million due to competition from cheaper biosimilars after losing exclusivity in 2023 [5][6]. Future Guidance - AbbVie raised its adjusted earnings guidance for 2025 to a range of $10.61 to $10.65 per share, up from a previous range of $10.38 to $10.58 [6][7]. - The company announced a 5.5% increase in its quarterly cash dividend to $1.73 per share, effective February 17, 2026 [8].

Core Insights - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets across various sectors including ETFs, commodities, technology, and pharmaceuticals [2] Group 1: Company Overview - Allka Research is recognized for its conservative investment approach, which consistently uncovers lucrative opportunities for clients [2] - The company aims to simplify investment strategies, making them accessible to both seasoned investors and newcomers [2] - Allka Research is committed to delivering substantial returns and strategic insights, fostering a community of informed investors [2] Group 2: Mission and Community Engagement - The mission of Allka Research is to provide thought-provoking analyses and informed perspectives to the Seeking Alpha community [2] - The company seeks to demystify investing, inspiring confidence in readers and enabling them to navigate the financial markets intelligently [2]

Core Insights - Allka Research has over two decades of experience in investment, focusing on identifying undervalued assets in various sectors including ETFs, commodities, technology, and pharmaceuticals [2] Group 1: Company Overview - Allka Research is recognized for its conservative investment approach, which consistently uncovers lucrative opportunities for clients [2] - The company aims to simplify investment strategies, making them accessible to both seasoned investors and newcomers [2] - Allka Research is committed to delivering substantial returns and strategic insights, fostering a community of informed investors [2] Group 2: Mission and Community Engagement - The mission of Allka Research is to provide thought-provoking analyses and informed perspectives to the Seeking Alpha community [2] - The company seeks to empower individuals financially by demystifying the complexities of investing [2] - Allka Research encourages readers to navigate the financial markets with confidence and understanding [2]